Zejula (niraparib) / Medison, J&J, GSK, Takeda, ZAI Lab  >>  Phase 2
Welcome,         Profile    Billing    Logout  

134 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zejula (niraparib) / GSK, J&J
2021-004278-76: Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance in patients with advanced ovarian cancer after complete initial surgery

Not yet recruiting
2
390
Europe
NIRAPARIB, Bevacizumab, [Niraparib], [bevacizumab], Capsule, hard, Concentrate for solution for infusion, ZEJULA, MVASI
ARCAGY-GINECO, GSK
Advanced ovarian, tubal or peritoneal cancer, Ovarian cancer, Diseases [C] - Cancer [C04]
 
 
2017-003353-41: Mesothelioma Stratified Therapy (MiST) - Including the following treatment arms: MiST 1 rucaparibMiST 2 abemaciclibMiST 3 pembrolizumab in combination with bemcentinibMiST 4 atezolizumab in combination with bevacizumabMiST 5 dostarlimab in combination with niraparib

Not yet recruiting
2
120
Europe
rucaparib, abemaciclib, Tecentriq, Avastin (for the 100mg/4ml presentation), Avastin (for 400 mg/16 ml presentation), Pembrolizumab, bemcentinib, KEYTRUDA (Pembrolizumab, MK3475), KEYTRUDA (pembrolizumab, MK3475), Niraparib, Dostarlimab, CO-338, LY2835219, R05541267/F03, RO4876646/F01, RO4876646/F02, MK-3475, BGB324, Tablet, Capsule, hard, Concentrate for solution for infusion, Solution for infusion, Capsule, Tecentriq, Avastin (for the 100mg/4ml presentation), Avastin (for 400 mg/16 ml presentation), KEYTRUDA (Pembrolizumab, MK3475), KEYTRUDA (pembrolizumab, MK3475), Niraparib
University of Leicester, The British Lung Foundation, Clovis Pharmaceuticals Inc., Eli Lilly & Company, Roche Pharma AG, Merck Sharp & Dohme Limited, BerGenBio ASA, GlaxoSmithKline Research & Development Limited
Malignant Mesothelioma (MM) - pleural and peritoneal, Mesothelioma is a universally lethal cancer caused by Asbestos. There has only been one licenced therapy since 2003. Accordingly there is a pressing need for effective therapy in the relapsed setting, Diseases [C] - Cancer [C04]
 
 
2018-004623-36: MEGALiT - a study in which the effect of established cancer drugs is investigated on new cancers that have a specific molecular signature MEGALiT - en studie där effekten av etablerade cancerläkemedel undersöks på nya cancersjukdomar som har en specifik molekylär signatur

Not yet recruiting
2
154
Europe
Tecentriq, Cotellic, Zejula, Everolimus, RO5514041/F04, Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Tecentriq, Cotellic, Zejula
Uppsala University Hospital, Roche AB
In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, Diseases [C] - Cancer [C04]
 
 
2017-004323-72: Clinical Trial to evaluate the efficacy and safety of Niraparib + Endocrin Therapy in luminal metastatic breast cancer patients. Ensayo clínico para evaluar la eficacia y seguridad de Niraparib + Terapia endocrina en pacientes luminales con cáncer de mama metastásico.

Not yet recruiting
2
23
Europe
Capsule, hard, Zejula
Medica Scientia Innovation Research (MedSIR), Tesaro,INC.
Advanced or metastatic HR-positive/HER2-negative breast cancer inpatients harboring either gBRCAms or gBRCAwt and HRD. Cáncer de mama avanzado o metastásico HR-positivo/HER2-negativo en pacientes con gBRCAms o gBRCAwt y HRD., Luminal advanced or metastatic breast cancer Cáncer de mama avanzado o metastásico en pacientes luminales, Diseases [C] - Cancer [C04]
 
 
2019-004771-40: ProTargetA Danish Nationwide Clinical Trial on Targeted Anti-Cancer Treatment based on Genomic Profiling

Not yet recruiting
2
300
Europe
Zejula, Capsule, hard, Concentrate and solvent for solution for infusion, Tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Alcensa, Tecentriq, Cotellic, Zelboraf, Herceptin, Perjeta, Kadcyla, Erivedge, Bavencio, Inlyta, Zejula, pemazyre, Retsevmo
Rigshospitalet, Roche, Pfizer
Eligible patients will have an advanced malignant disease for which standard treatment options are no longer available or feasible and acceptable performance status and organ function. Patienter med fremskreden og/eller metastatisk solid tumor, som har oplevet progression under standardbehandling, eller som er intolerante over for standardbehandling, Patients with advanced cancer without curative therapeutic options Patienter med fremskreden kræft uden mulighed for kurativ behandling, Diseases [C] - Cancer [C04]
 
 
2018-003736-77: A MULTICENTER TRIAL OF A NEW CUSTOMIZED DOSING (RATIONAL ADJUSTMENT OF DOSE TO REDUCE ADVERSE REACTIONS “RADAR” DOSING) OF NIRAPARIB AS MAINTENANCE THERAPY IN PLATINUM SENSITIVE OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL RECURRENT CANCER PATIENTS

Not yet recruiting
2
105
Europe
Niraparib, Niraparib, Capsule, hard
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, GSK, TESARO
Ovarian, fallopian tube or primary peritoneal recurrent cancer, Ovarian, fallopian tube or peritoneal recurrent cancer, Diseases [C] - Cancer [C04]
 
 
2020-000109-10: A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for PD-L1 expression and germline or somatic mutations in the DNA repair genes Studio prospettico, multicentrico, di fase II, a braccio singolo, sulla combinazione Niraparib+Dostarlimab in pazienti con carcinoma polmonare non a piccole cellule avanzato e mesotelioma pleurico maligno, positivo per espressione di PD-L1 e mutazioni germinali o somatiche nei geni di riparo del danno al DNA

Ongoing
2
70
Europe
niraparib, DOSTARLIMAB, [MK-4827], [TSR-042], Capsule, hard, Solution for injection, ZEJULA, DOSTARLIMAB
DIPARTIMENTO DI ONCOLOGIA-UNIVERSITA' DEGLI STUDI DI TORINO, GSK
patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for PD-L1 expression and germ or somatic mutations in DNA damage repair genes pazienti con carcinoma polmonare non a piccole cellule avanzato e mesotelioma pleurico maligno, positivo per espressione di PD-L1 e mutazioni germinali o somatiche nei geni di riparo del danno al DNA, patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for PD-L1 expression and germ or somatic mutations in DNA damage repair genes pazienti con carcinoma polmonare non a piccole cellule avanzato e mesotelioma pleurico maligno, positivo per espressione di PD-L1 e mutazioni germinali o somatiche nei geni di riparo del danno al DNA, Diseases [C] - Cancer [C04]
 
 
2020-002766-14: Combination of Niraparib and Dostarlimab in patients with DNA repair-deficient or platinum-sensitive solid tumors

Not yet recruiting
2
800
Europe
Niraparib, Dostarlimab, TSR-042, Capsule, Solution for infusion
Gustave Roussy, GSK/Tesaro
Patients with DNA repair-deficient or platinum-sensitive solid tumors, Solid tumors, Diseases [C] - Cancer [C04]
 
 
2019-004875-38: The induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) Trattamento di induzione e mantenimento con inibitore di PARP e immunoterapia nel carcinoma a cellule squamose della testa e del collo (HNSCC) HPV-negativo

Ongoing
2
49
Europe
niraparib, dostarlimab, [niraparib], [TSR-042 (also known as GSK4057190) and WBP-285], Capsule, hard, Solution for infusion, Zejula
Fondazione GONO, GLAXOSMITHKLINE LLC
HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) Carcinoma a cellule squamose della testa e del collo (HNSCC) HPV-negativo, HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) Carcinoma a cellule squamose della testa e del collo (HNSCC) HPV-negativo, Diseases [C] - Cancer [C04]
 
 
OVARIO, NCT03326193: A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Checkmark From OVARIO trial in combination with bevacizumab for advanced ovarian cancer
Jan 2020 - Jan 2020: From OVARIO trial in combination with bevacizumab for advanced ovarian cancer
Active, not recruiting
2
105
US
Niraparib, ZEJULA, Bevacizumab, Avastin
Tesaro, Inc.
Ovarian Neoplasms
12/20
05/24
NCT03016338: Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

Active, not recruiting
2
51
Canada
Niraparib, MK4827, TSR-042, Dostarlimab
University Health Network, Toronto, Tesaro, Inc.
Endometrial Cancer
01/21
12/25
Galahad, NCT02854436 / 2016-002057-38: An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

Checkmark From GALAHAD trial for mCPRC
Sep 2019 - Sep 2019: From GALAHAD trial for mCPRC
Completed
2
289
Europe, Canada, US, RoW
Niraparib, JNJ-64091742
Janssen Research & Development, LLC
Prostatic Neoplasms
01/21
08/23
2020-004414-35: Improving public cancer care by implementing precision medicine in Norway

Not yet recruiting
2
2000
Europe
Alpelisib, Fulvestrant, imatinib, Hydroxyurea, bortezomib, capmatinib, Dactinomycin, tepotinib, dostarlimab, Capsule, hard, Injection, Infusion, Tablet, Capsule, Solution for injection, Powder and solvent for suspension for injection, Powder for solution for injection, Concentrate for solution for infusion, Alecensa, Erivedge, Phesgo, Rozlytrek, Tecentriq, Avastin, Zelboraf, Cotellic, Mekinist, Tafinlar, Alkeran, Piqray, Lynparza, Pemazyre, Tabrecta, Retsevmo, Tepmetko, Gavreto, Zejula
Oslo University Hospital, Oslo University Hospital
Patients with a biomarker indicating response to IMP can be included in IMPRESS-Norway. Patients with disease characteristics covered in present indications for the IMP are not eligible., Patients with a biomarker indicating response to the study drug can be included in the trial. Patients with disease characteristics covered in present indications for the study drug are not eligible., Diseases [C] - Cancer [C04]
 
 
2019-003702-27: NA NA

Not yet recruiting
2
12
Europe
GSK 3985771, MK-4827, Capsule, Zejula 100 mg gélules
Assistance Publique – Hôpitaux de Paris (AP-HP), CRC
Patients with HER2 positive disease. NA, PALB2 germline heterozygous mutation carrier, wild type BRCA1&2 affected with metastatic breast cancer in first metastatic treatment line or beyond NA, Diseases [C] - Cancer [C04]
 
 
2018-004207-39: Mirvetuximab Soravtansine in patients with high expression of folate receptor alpha in their tumor and recurrent ovarian cancer

Not yet recruiting
2
136
Europe
Mirvetuximab Soravtansine, Powder and solvent for concentrate for solution for infusion, Solution for infusion, Capsule, hard, Film-coated tablet, , Caelyx, Carboplatin Kabi, Paclitaxel-GRY®, Gemedac®, Zejula, Lynparza, Rubraca
AGO Research GmbH, ImmunoGen, Inc.
This trial evaluates the efficacy and safety of Mirvetuximab soravtansine (IMGN853) plus Carboplatin chemotherapy in FRα high patients with recurrent ovarian cancer who are eligible for platinum-based chemotherapy., Safety and efficacy for carboplatin with Mirvetuximab soravtansine (IMGN853) compared to carboplatin combination chemotherapy, Diseases [C] - Cancer [C04]
 
 
2020-002667-53: EXTENSION STUDY FOR PATIENTS WHO HAVE COMPLETED A PRIOR GLAXOSMITHKLINE/TESARO-SPONSORED NIRAPARIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH NIRAPARIB

Not yet recruiting
2
59
Europe
NIRAPARIB, GSK 3985771, MK-4827, Capsule, Film-coated tablet, Zejula 100mg hard capsules, Zejula 100 mg film-coated tablets
GlaxoSmithKline Research & Development Limited, GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT, GSK
advanced ovarian, breast, or prostate cancer, advanced ovarian, breast, or prostate cancer, Diseases [C] - Cancer [C04]
 
 
ANNIE, NCT04376073: Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer

Recruiting
2
40
RoW
Niraparib, Anlotinib
Jihong Liu
Platinum-resistant Ovarian Cancer
12/21
03/22
NCT04715620: Niraparib Combined With Radiotherapy in rGBM

Recruiting
2
30
RoW
Niraparib
Tianjin Huanhu Hospital
Recurrent Glioblastoma
01/22
01/23
NCT04409002: Niraparib + Dostarlimab + RT in Pancreatic Cancer

Completed
2
18
US
Niraparib, Zejula, Dostarlimab, Radiation
Massachusetts General Hospital, Tesaro, Inc.
Pancreatic Cancer, Metastatic Pancreatic Cancer
01/22
02/22
NCT03925350: Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

Recruiting
2
41
US
Niraparib
California Pacific Medical Center Research Institute, Tesaro, Inc., Vanderbilt-Ingram Cancer Center, Huntsman Cancer Institute
Metastatic Melanoma
02/22
02/23
2021-005392-39: OPAL Master ProtocolPhase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of Treatments in Participants with Ovarian Cancer (OPAL).OPAL-Supplement CCohort C: Open-Label Phase 2, Randomized, Controlled Multicenter Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants with Homologous Recombination-Deficient Stage III/IV Ovarian Cancer. Estudio en paraguas de múltiples cohortes en fase IB/II para evaluar la seguridad y la eficacia de nuevos tratamientos y/o combinaciones de tratamientos en participantes con cáncer de ovario (OPAL).Cohorte C: Estudio de fase II, abierto, aleatorizado, controlado y multicéntrico para comparar niraparib frente a quimioterapia doble con platino-taxano como tratamiento neoadyuvante en participantes con cáncer de ovario en estadio III/IV con deficiencia de recombinación homóloga.

Not yet recruiting
2
84
Europe
Niraparib, GSK3985771, Capsule, Zejula
GlaxoSmithKline, S.A., GlaxoSmithKline Research and Development Ltd., GlaxoSmithkline R&D Ltd.
Ovarian cancer Cáncer de ovario, Ovarian Cancer Cáncer de ovario, Diseases [C] - Cancer [C04]
 
 
NCT04217798: Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer

Recruiting
2
36
RoW
Niraparib, oral etoposide
Peking Union Medical College Hospital, Zai Lab (Shanghai) Co., Ltd.
Ovarian Cancer
03/22
06/22
AVANIRA3, NCT04556071: Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

Recruiting
2
32
RoW
Niraparib, Zejula, Bevacizumab, Avastin
Xiaoxiang Chen
Ovarian Neoplasms, Fallopian Tube Neoplasms, Endocrine Gland Neoplasms, Neoplasms by Site, Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Carcinoma, Ovarian Epithelial, Ovarian Diseases, Adnexal Diseases, Genital Diseases, Female, Endocrine System Diseases, Gonadal Disorders, Carcinoma, Bevacizumab, Enzyme Inhibitors, Antineoplastic Agents, Molecular Mechanisms of Pharmacological Action, Angiogenesis, BRCA1 Mutation, BRCA2 Mutation, Homologous Recombination Deficiency
03/22
10/22
COHORT-A, NCT05751629: Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Completed
2
41
US
Dostarlimab, TSR-042, Bevacizumab, Avastin, Niraparib, ZEJULA
Tesaro, Inc.
Ovarian Neoplasm
04/22
04/22
CQGOG0101, NCT04395612: Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer

Recruiting
2
38
RoW
niraparib combined with brivanib, Treatment group1, niraparib combined with toripalimab, Treatment group2
Chongqing University Cancer Hospital
Cervical Cancer
04/22
07/22
2021-003042-20: Study assessing the efficacy of niraparib as first line therapy with pancreatic cancer patient's Etude évaluant l'efficacité du niraparib en première ligne de traitement chez les patients atteints d'un cancer du pancréas

Not yet recruiting
2
28
Europe
Capsule, ZEJULA
Centre Léon Bérard, GlaxoSmithKline (GSK) Group Company
Patients with metastatic homologous repair-deficient pancreatic cancer Patients présentant un cancer du pancréas métastatique avec un déficit de la recombinaison homologue, Pancreatic cancer Cancer du pancréas, Diseases [C] - Cancer [C04]
 
 
NCT04423185: PLATFORM Study of Precision Medicine for Rare Tumors

Not yet recruiting
2
770
NA
Almonertinib 110 MG, HS-10296, AMEILE, Dacomitinib 45 MG, Vizimpro, Alectinib 150 MG, Alecensa, Crizotinib 250 MG, Xalkori, Pyrotinib 160/80 MG, SHR-1258, Imatinib 400 MG, Gleevec, Niraparib 200/300 MG, Niraparix, Palbociclib 125mg, Ibrance, Vemurafenib 240 MG, Zelboraf, Sintilimab 100MG, Tyvyt, Atezolizumab 1680 MG, TECENTRIQ
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rare Tumor
07/22
07/23
NCT04885413: An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients

Recruiting
2
37
RoW
Niraparib in Combination With Anti-PD1 Antibody, sintilimab
Sun Yat-sen University
Recurrent/ Advanced Stage Endometrial Cancer Patients
08/22
06/23
ChiCTR2100047345: Anlotinib Combined with Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma (CC-ANNIE): a Single-center, Single-arm, Phase 2 Trial

Recruiting
2
20
 
Anlotinib combined with Niraparib Dual Therapy
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Corporate sponsorship
Ovarian Clear Cell Carcinoma
 
 
CHANGEABLE, NCT04508803: Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer

Recruiting
2
37
RoW
HX008，Niraparib, HX008，Niraparib，Trastuzumab, HX008，Niraparib，Pyrrolitinib
Fudan University
Treatment Efficacy
11/22
12/22
ChiCTR2000039701: Efficacy and safety of Niraparib combined with radiotherapy in patients with recurrent glioblastoma

Recruiting
2
30
 
Niraparib 200mg QD
Tianjin Huanhu Hospital; Tianjin Huanhu Hospital, Zai Lab
Glioblastoma
 
 
ChiCTR2000037709: An open-label, single arm, phase II trial of niraparib maintenance treatment in patients with primary, platinum resistant ovarian cancer and Exploration of PARPi resistance mechanism

Recruiting
2
43
 
Niraparib
Obstetrics & Gynecology Hospital of Fudan University; Level of the institution：, beijing kanghua foundation of development of triditional chinese and western medicine
ovarian cancer
 
 
2022-004188-25: Phase II, single arm, multicenter, open-label study of PARP inhibitors + cisplatin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma Studio di fase II; singolo braccio, multicentrico, in aperto, che valuta la combinazione PARP inibitore + cisplatino in pazienti affetti da carcinoma adenoide cistico recidivo e/o metastatico

Not yet recruiting
2
27
Europe
cisplatino, zejula, [cisplatino], [zeluja], Concentrate for solution for injection/infusion, Capsule, hard, ZEJULA - 100 MG - CAPSULA RIGIDA - USO ORALE - BLISTER (PCTFE/PVC/ALU) - 84 X 1 CAPSULE (DOSE UNITARIA)
AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA, FFRB _REGIONE LOMBARDIA
patients with recurrent and/or Metastatic Adenoid Cystic Carcinoma pazienti affetti da carcinoma adenoide cistico recidivo e/o metastatico, patients with recurrent and/or Metastatic Adenoid Cystic Carcinoma pazienti affetti da carcinoma adenoide cistico recidivo e/o metastatico, Diseases [C] - Cancer [C04]
 
 
NCT05311579: Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

Recruiting
2
36
RoW
Niraparib plus anlotinib
Lei Li
Ovarian Carcinoma, Survival Outcomes, Adverse Events, Niraparib, Anlotinib, CA125, Chemotherapy, Targeted Therapy, Recurrent Ovarian Cancer
03/23
03/24
NIRVANA-R, NCT04734665: Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

Recruiting
2
44
RoW
Niraparib-Bevacizumab
Yonsei University, Takeda
Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
03/23
03/24
NADiR, NCT04837209: Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

Recruiting
2
32
US
Niraparib, Zejula, Dostarlimab, TSR-042, WBP-285, Radiation therapy
Massachusetts General Hospital, Sibley Memorial Hospital, Duke University, University of Pennsylvania
Breast Cancer, Triple Negative Breast Cancer
04/25
12/29
NIRA-PANC, NCT03553004: Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (): a Phase 2 Trial

Active, not recruiting
2
18
US
Niraparib Treatment
University of Kansas Medical Center, Tesaro, Inc.
Pancreatic Cancer
04/23
02/25
PRIME, NCT04681469: Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC

Recruiting
2
49
Europe
Niraparib, Dostarlimab
Gruppo Oncologico del Nord-Ovest
Head and Neck Squamous Cell Carcinoma
06/23
06/28
NCT05162872: Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma

Recruiting
2
99
RoW
Niraparib，Sintilimab
Sun Yat-sen University
Nasopharyngeal Carcinoma
06/23
10/23
STAR, NCT04068753: Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

Recruiting
2
66
US
Niraparib, dostarlimab
University of Oklahoma, Tesaro, Inc.
Recurrent Cervix Cancer, Progressive Cervix Cancer
07/25
07/27
NANT, NCT04507841: Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Recruiting
2
53
RoW
Niraparib
Tongji Hospital, Qilu Hospital of Shandong University, Hubei Cancer Hospital, Hunan Cancer Hospital, Obstetrics and Gynecology Hospital of Zhejiang University, Sun Yat-sen University, Anhui Provincial Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Suzhou Medical College, Renmin Hospital of Wuhan University, Guangdong Provincial People's Hospital
Ovarian Cancer
07/23
07/23
NCT04716686: Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

Recruiting
2
83
RoW
Niraparib
Shandong University, Sun Yat-sen University, Tongji Hospital, Women's Hospital School Of Medicine Zhejiang University, Zai Lab (Shanghai) Co., Ltd.
Endometrial Carcinoma, Serous Carcinoma
12/25
12/26
EUDARIO, NCT03783949 / 2017-004058-40: European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer

Completed
2
122
Europe
Ganetespib, Niraparib, Carboplatin, Paclitaxel, Gemcitabine
Universitaire Ziekenhuizen KU Leuven, European Commission
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
09/23
09/23
Bohème, NCT05412706: Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy

Withdrawn
2
46
NA
Niraparib, Zejula
Ospedale Policlinico San Martino, CRO "Centro Clinical Trials" IRCCS Ospedale Policlinico San Martino, Laboratory Molecular Oncology Candiolo Cancer Institute IRCCS - Candiolo (Torino)
Metastatic Colorectal Cancer
09/23
09/23
NCT03601923: Niraparib in Patients With Pancreatic Cancer

Active, not recruiting
2
32
US
Niraparib, Zejula
Dana-Farber Cancer Institute, Tesaro, Inc.
Pancreatic Cancer
09/24
02/25
NEOPRIMA, NCT04284852: Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting

Completed
2
20
RoW
Niraparib, Zejula
The University of Hong Kong
Ovarian Cancer
10/23
10/23
NCT05641506: A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer

Not yet recruiting
2
50
RoW
Yangzheng Xiaoji, Niraparib
Sichuan Cancer Hospital and Research Institute
Ovarian Cancer
10/23
05/25
MiST, NCT03654833: Mesothelioma Stratified Therapy () : A Multi-drug Phase II Trial in Malignant Mesothelioma

Active, not recruiting
2
186
Europe
Rucaparib, CO-338, Abemaciclib, LY2835219, pembrolizumab & bemcentinib, Keytruda; BGB324, Atezolizumab & Bevacizumab, MPDL3280A; Avastin, Dostarlimab and Niraparib, Zejula
University of Leicester, British Lung Foundation, Clovis Oncology, Inc., Eli Lilly and Company, Merck Sharp & Dohme LLC, BerGenBio ASA, Roche Pharma AG, University Hospitals, Leicester, The Christie NHS Foundation Trust, GlaxoSmithKline
Mesothelioma, Malignant
10/23
10/23
NCT03840967: A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

Terminated
2
14
US
Niraparib, Zejula
Shadia Jalal, MD, GlaxoSmithKline, Indiana University School of Medicine
Esophageal Cancer, Gastric Cancer, Adenocarcinoma
11/22
02/23
BRAND, NCT06141265: Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab

Recruiting
2
116
RoW
Niraparib
Peking University Cancer Hospital & Institute
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
09/26
09/27
NADIR, NCT04037254: Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer

Suspended
2
180
Canada, US
Gonadotrophin Releasing Hormone, AY-24031, D-His-6-Pro-8-NEt-LHRH, Follicle Stimulating Hormone-Releasing Factor, GN-RH, GnRH, Gonadoliberin, Gonadorelin, Gonadorelinum, gonadotropin-releasing hormone, Hoe- 471, LH-RF, LH-RH, LH/FSH-RF, LH/FSH-RH, LHRH, Luliberin, Luteinising Hormone-Releasing Factor, Luteinizing Hormone-Releasing Factor, luteinizing hormone-releasing hormone, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Niraparib, MK-4827, MK4827
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
01/28
12/28
Newton, NCT03891576: Study (NEW Dosing mainTenance Therapy Ovarian caNcer)

Active, not recruiting
2
83
Europe
Niraparib, Zejula
Mario Negri Institute for Pharmacological Research, North Eastern German Society of Gynaecological Oncology
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
09/24
12/24
ChiCTR2000035853: An open-label, single arm, phase II trial of niraparib plus anlotinib in patients with recurrent, metastatic Endometrial Cancer

Not yet recruiting
2
86
 
Niraparib; anlotinib
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, Scientific research funds and corporate sponsorship
Ovarian cancer
 
 
ChiCTR2000039310: Platform Study of Genotyping Guided Precision Medicine for Rare Tumors in China

Recruiting
2
208
 
Almonertinib, 110mg, qd ;Dacomitinib, 450mg, qd ;Alectinib, 600mg, bid ;Crizotinib, 250mg, bid ;Zelboraf, 960mg, bid ;Niraparib,200-300mg,qd ;Pyrotinib, 400mg, qd ;Imatinib, 400mg, bid ;Palbociclib, 125mg,*21d, q28d ;Sintilimab, 200mg, q21d ;Atezolizumab, 1200mg, q21d ;atezolizumab, 1200mg, q21d ;atezolizumab, 1200mg, q21d
National Cancer Center/National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital of Chinese Academy of Medical Sciences, self-raised
Rare Tumors
 
 
NIRVANA-1, NCT05183984: Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

Recruiting
2
390
Europe, Japan
Chemotherapy, Bevacizumab-Awwb, Niraparib
ARCAGY/ GINECO GROUP
Ovarian Cancer
02/27
02/30
QPT-ORE-004, NCT05335993: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Active, not recruiting
2
10
US
Oregovomab, MAb-B43.13, Monoclonal antibody B43.13, Niraparib, Zejula
CanariaBio Inc., Veristat, LLC
Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Peritoneal Cancer, Recurrent Carcinoma of Ovary, Adenocarcinoma of Ovary
03/24
12/24
NCT06237205: Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

Not yet recruiting
2
33
NA
Niraparib
Korea University Anam Hospital, Takeda, Korean Cancer Study Group
Efficacy
06/26
06/27
NIRADO, NCT04779151: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab

Suspended
2
51
Europe
Dostarlimab, Niraparib
Gustave Roussy, Cancer Campus, Grand Paris
Urothelial Bladder Cancer, Gastric Adenocarcinoma, Gastro-oesophageal Adenocarcinoma, Head and Neck Cancer, Biliary Tract Cancer, Platinum-sensitive Urothelial Bladder Cancer, Clear Cell Renal Cell Carcinoma, Pancreatic Ductal Adenocarcinoma
12/24
12/27
NCT05385068: A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi

Not yet recruiting
2
35
NA
Niraparib, Anlotinib
Peking Union Medical College Hospital, Zai Lab (Shanghai) Co., Ltd.
Epithelial Ovarian Cancer
03/24
09/24
ELEMENT, NCT06201234: Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Not yet recruiting
2
176
Europe
Niraparib + Elacestrant, Niraparib
German Breast Group, Stemline Therapeutics, Inc., GlaxoSmithKline
Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, PALB2 Gene Mutation
03/28
03/28
KNIGHTS, NCT06212583: High-Risk Metachronous Oligometastatic Prostate Cancer Trial

Recruiting
2
88
US
niraparib/abiraterone acetate, Stereotactic ablative radiation therapy (SABR), Androgen deprivation therapy (ADT)
University of Maryland, Baltimore, Janssen Scientific Affairs, LLC
Prostate Cancer, Oligometastatic Disease
12/28
12/29
ProTarget, NCT04341181: - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Recruiting
2
300
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Avelumab, Bavencio, Axitinib, Inlyta, Erlotinib, Tarceva, Vemurafenib plus Cobimetinib (combination), Zelboraf plus Cotellic (combination), Trastuzumab plus Pertuzumab (combination), Herceptin plus Perjeta (combination), Trastuzumab emtansine, Kadcyla, Vismodegib, Erivedge, Niraparib, Zejula
Ulrik Lassen, Roche Pharma AG, Pfizer, GlaxoSmithKline
Cancer, Tumors, Neoplasms, Neoplasia
04/24
04/25
PLATPARP, NCT04288687: A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

Active, not recruiting
2
12
US
Niraparib Pill
Abramson Cancer Center at Penn Medicine
Prostate Adenocarcinoma
06/24
06/24
NCT04313504: Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

Active, not recruiting
2
23
US
Niraparib, ZEJULA, Dostarlimab, TSR-042
Trisha Wise-Draper, GlaxoSmithKline
Head and Neck Cancer
06/24
06/27
PAVO, NCT05169437: Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

Active, not recruiting
2
22
US
Niraparib, Zejula
Tempus AI, GlaxoSmithKline
Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer
06/24
01/25
NCT05162196: The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer

Not yet recruiting
2
57
NA
SBRT, Toripalimab, Niraparib
Wuhan University
Recurrent Small Cell Lung Cancer
06/24
12/24
UNITO-001, NCT04940637: - Study in HRR/PDL1 Positive MPM/NSCLC

Recruiting
2
70
Europe
niraparib and dostarlimab, no other intervention
University of Turin, Italy
Lung Cancer, Mesothelioma
06/24
06/25
NCT04080284: Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

Recruiting
2
45
US
Niraparib, ZEJULA
Northwell Health, Tesaro, Inc.
Endometrial Cancer, Papillary Serous Endometrial Carcinoma, Uterine Serous Carcinoma, Endometrial Carcinoma, Cancer of the Endometrium
07/24
07/26
NCT06365970: Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Not yet recruiting
2
20
US
Niraparib, Zejula, Dostarlimab, Jemperli
Ibrahim Halil Sahin, GlaxoSmithKline
MMR-D/MSI-H Colorectal Cancers
07/26
07/27
NCT04584255: Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Recruiting
2
62
US
Niraparib, Zejula, Dostarlimab, TSR042
Dana-Farber Cancer Institute, Translational Breast Cancer Research Consortium, Johns Hopkins University, GlaxoSmithKline
Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
07/25
07/29
NCT06433219: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Not yet recruiting
2
60
Europe, US
Tuvusertib (M1774), M1774, VXc-400, VRT-1363004, substance code MSC2584415A, Niraparib, GSK3985771, MK-4827, Lartesertib (M4076), M4076, substance code MSC2585823A
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Ovarian Cancer
01/28
01/28
NCT04030559: Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Recruiting
2
30
US
Niraparib, MK-4827, MK4827, Niraparib Tosylate Monohydrate, Zejula, Radical Prostatectomy, Prostatovesiculectomy
Marc Dall'Era, MD, National Cancer Institute (NCI), Janssen, LP
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CDK12 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, DNA Damage Response Gene Mutation, DNA Repair Gene Mutation, FANCA Gene Mutation, FANCD2 Gene Mutation, FANCL Gene Mutation, GEN1 Gene Mutation, NBN Gene Mutation, Prostate Carcinoma, RAD51 Gene Mutation, RAD51C Gene Mutation
08/24
02/25
DIDO, NCT04983745: Niraparib and Dostarlimab in HRD Solid Tumors

Recruiting
2
30
US
Combination drug
West Cancer Center
Homologous Recombination Deficient Solid Tumors
08/24
08/25
ANALLISA, NCT06180356: Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

Not yet recruiting
2
30
NA
Niraparib oral tablets
MedSIR
Ovarian Cancer, Oligometastatic Disease, Serous Ovarian Tumor
10/25
11/25
NCT04493060: Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Active, not recruiting
2
22
US
Dostarlimab, ANB011, Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer, TSR 042, TSR-042, TSR042, Niraparib, MK-4827, MK4827
Mayo Clinic, National Cancer Institute (NCI)
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
12/23
09/24
PALB2-PARPi-01, NCT05232006: PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers

Not yet recruiting
2
12
NA
Niraparib
Assistance Publique - Hôpitaux de Paris
Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
09/24
05/30
NCT05689021: CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Recruiting
2
30
US
Abiraterone Acetate/Niraparib, Abiraterone Acetate and Niraparib Tosylate Monohydrate, Abiraterone Acetate/Niraparib Tosylate Monohydrate, Akeega, CJNJ-67652000, Niraparib and Abiraterone Acetate, Niraparib Tosylate Monohydrate and Abiraterone Acetate, Niraparib Tosylate Monohydrate/Abiraterone Acetate, Niraparib/Abiraterone Acetate, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone
Mayo Clinic
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
09/24
09/25
NIPAVect, NCT03983993: Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer

Active, not recruiting
2
40
US
Niraparib, MK-4827, Zejula, Panitumumab, ABX-EGF, Vectibix
Emory University, GlaxoSmithKline, National Institutes of Health (NIH), National Cancer Institute (NCI)
Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Microsatellite Stable, RAS Wild Type, Stage IV Colorectal Cancer AJCC v8, MSI-H Colorectal Cancer
10/24
10/24
NCT05126342: Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Not yet recruiting
2
100
NA
Niraparib, Zejula, Dostarlimab, TSR-042
AGO Research GmbH, GlaxoSmithKline
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer
11/24
11/26
NCT04992013: Niraparib in Tumors Metastatic to the CNS

Recruiting
2
20
US
Niraparib, Zejula
Massachusetts General Hospital, GlaxoSmithKline
Metastatic Cancer, Central Nervous System Cancer
12/24
12/26
HARMONY, NCT06392841: Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Not yet recruiting
2
64
NA
Androgen Deprivation Therapy (ADT), Niraparib/Abiraterone Acetate DAT, Akeega, Abiraterone Acetate, Zytiga, Prednisone, Rayos, Deltasone, Prednisone Intensol, Docetaxel, Docefrez, Taxotere
Qian Qin, UT Southwestern Comprehensive Cancer Center, Janssen, LP
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, PALB2 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation
04/27
04/28
ChiCTR2100046269: A phase II trial of combination of niraparib and anlotinib in patients with recurrent small cell lung cancer (SCLC)

Recruiting
2
62
 
Niraparib in combination with Anlotinib
Jilin Provice Cancer Hospital; Jilin Provice Cancer Hospital, Zaiding pharmaceutical (Shanghai) Co. , Ltd.
small cell lung cancer(SCLC)
 
 
NERO, NCT05455424: Niraparib Efficacy in Patient With Unresectable Mesothelioma

Active, not recruiting
2
88
Europe
Niraparib Oral Product, Zejula, Active Symptom Control
University Hospital Southampton NHS Foundation Trust, University of Southampton, British Lung Foundation
Mesothelioma, Malignant
12/24
12/24
NCT05461690: Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency

Not yet recruiting
2
50
NA
Niraparib, Zejula
Zhejiang Cancer Hospital, Sun Yat-sen University, Hunan Cancer Hospital, Fujian Cancer Hospital, Zhejiang University, Taizhou Hospital of Zhejiang Province
Homologous Recombination Deficiency, Triple Negative Breast Cancer
12/24
06/25
NCT05870761: Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

Recruiting
2
35
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Dostarlimab, ANB011, Dostarlimab-gxly, Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer, Jemperli, TSR 042, TSR-042, TSR042, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Niraparib, MK-4827, MK4827
Casey Cosgrove
Recurrent Endometrial Serous Adenocarcinoma
12/24
12/24
NCI-2021-12582, NCT05174455: Niraparib for the Treatment of Leiomyosarcoma

Withdrawn
2
22
NA
Niraparib Tosylate Monohydrate, Zejula
David Liebner, MD
Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Retroperitoneal Sarcoma AJCC v8, Stage IIIA Retroperitoneal Sarcoma AJCC v8, Stage IIIB Retroperitoneal Sarcoma AJCC v8, Stage IV Retroperitoneal Sarcoma AJCC v8, Unresectable Leiomyosarcoma
12/24
12/25
RAISE, NCT05718323: Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

Recruiting
2
44
Europe
Niraparib
ETOP IBCSG Partners Foundation, GlaxoSmithKline, Development Limited
SCLC,Extensive Stage, SLFN11-positive
05/25
10/25
NCT04701307: Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Active, not recruiting
2
48
US
Dostarlimab, ANB011, Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer, TSR 042, TSR-042, TSR042, Niraparib, MK-4827, MK4827
M.D. Anderson Cancer Center
Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
05/25
05/25
UPSTREAM, NCT03088059 / 2017-000086-74: Biomarker-based Study in R/M SCCHN

Checkmark Data from UPSTREAM trial in combination with monalizumab for SCCHN
Oct 2019 - Oct 2019: Data from UPSTREAM trial in combination with monalizumab for SCCHN
Active, not recruiting
2
340
Europe
Afatinib, Palbociclib, standard of care, IPH2201, Monalizumab, Durvalumab, Niraparib, INCAGN01876
European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Squamous Cell of Head and Neck
06/25
12/25
NCT03983226: Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Recruiting
2
167
RoW
Surgery, secondary cytoreduction, carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin..., third-line therapy, Niraparib, maintenance therapy
Shanghai Gynecologic Oncology Group, Fudan University, Shanghai Jiao Tong University School of Medicine, Zhejiang Cancer Hospital, Sun Yat-sen University
Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
06/25
12/26
OU-SCC-PI-4G, NCT05297864: PARP Inhibition for Gliomas (PI-4G or π4g)

Terminated
2
15
US
Niraparib
University of Oklahoma, GlaxoSmithKline
Recurrent Glioblastoma, Recurrent Astrocytoma, Recurrent Oligodendroglioma, Recurrent Glioma
11/23
02/24
NCT05065021: Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Recruiting
2
40
Canada
Niraparib, ZEJULA, Dostarlimab, Bevacizumab, Paclitaxel
University Health Network, Toronto, GlaxoSmithKline
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High Grade Serous Cancer, High Grade Endometrioid Cancer
06/25
06/25
NCT06036966: The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients

Not yet recruiting
2
34
NA
Hetrombopag
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Thrombocytopenia
07/25
07/25
NCT05700721: Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Recruiting
2
120
US
Niraparib, MK-4827, Dostarlimab
M.D. Anderson Cancer Center
Brain Metastases
08/25
08/27
NCT05526989: Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Recruiting
2
25
US
Dostarlimab, Jemperli, Niraparib, Zejula
H. Lee Moffitt Cancer Center and Research Institute, GlaxoSmithKline
Penile Carcinoma
10/25
10/26
NCT05961124: Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

Recruiting
2
40
Canada
Niraparib, Zejula
Sunnybrook Health Sciences Centre, GlaxoSmithKline
Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, High Grade Ovarian Serous Adenocarcinoma
09/25
09/27
N-Plus, NCT05460000: A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

Not yet recruiting
2
640
NA
3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy
North Eastern German Society of Gynaecological Oncology, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma
05/27
05/32
NCT04641247: A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Active, not recruiting
2
26
Europe, Canada, US, RoW
Niraparib
GlaxoSmithKline
Ovarian Neoplasms, Breast Neoplasms
11/25
11/25
NCT04221503: Niraparib/TTFields in GBM

Active, not recruiting
2
30
US
Niraparib, ZEJULA, Optune, Tumor Treatment Fields (TTFields), Planned surgical resection, Tumor Resection
University of Pennsylvania, Tesaro, Inc., NovoCure Ltd.
Glioblastoma, Recurrent Glioblastoma, GBM
12/25
12/25
NCT04592237: Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Active, not recruiting
2
120
US
Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cetrelimab, JNJ 63723283, JNJ-63723283, JNJ63723283, WHO 10757, Niraparib, MK-4827, MK4827
M.D. Anderson Cancer Center, Janssen Pharmaceutica
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
12/25
12/25
 

Download Options